STOCK TITAN

Prime Medicine (PRME) Stock Price, News & Analysis

PRME NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
74 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+23.2% close of October 28, 2026
1-year change
+0.5% closing prices, November 17, 2025 to November 17, 2026
1-month change
+10.7% closing prices, October 16, 2026 to November 17, 2026

Company Description

Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company focused on research and development in gene editing and genetic medicines. According to the company’s public disclosures, Prime Medicine is dedicated to creating and delivering a new class of differentiated one-time curative genetic therapies using its proprietary Prime Editing platform. This platform is described as a versatile, precise and efficient gene editing technology designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.

Prime Editors, the tools at the core of Prime Editing, are described by the company as having the potential to repair almost all types of genetic mutations and to work in many different tissues, organs and cell types. Based on the company’s statements, these capabilities could unlock opportunities across thousands of potential indications, spanning a broad range of genetic and other serious diseases.

Prime Editing platform and therapeutic focus

Prime Medicine states that it is deploying its Prime Editing platform to develop one-time curative genetic therapies. The company highlights the modularity of this platform, meaning that once a Prime Editing approach is established for a particular disease setting, it may be adapted for additional targets and indications. The company’s disclosures emphasize that Prime Editing does not induce double-strand breaks in DNA, and that this mechanism may be better tolerated by hematopoietic stem cells and other cell types than approaches that rely on such breaks, based on early clinical and preclinical observations described by the company.

Prime Medicine reports that it is progressing a diversified portfolio of investigational therapeutic programs organized around three core areas of focus: liver, lung, and immunology and oncology. Within each of these core areas, the company states that it is initially concentrating on a set of high value programs that target diseases with well-understood biology and clearly defined clinical development and regulatory paths. These initial programs are expected, according to the company, to provide foundations for expansion into additional opportunities within the same organ systems or disease areas.

Key pipeline programs and disease areas

In its public communications, Prime Medicine describes several named investigational programs and disease targets. The company is advancing in vivo programs aimed at two large genetic liver diseases: Wilson’s Disease (WD) and Alpha-1 Antitrypsin Deficiency (AATD). It has identified PM577 as a Prime Editor candidate for the treatment of H1069Q-driven Wilson’s Disease and PM647 as a development candidate for AATD, and has discussed plans to file investigational new drug (IND) and/or clinical trial applications (CTA) for these programs on defined timelines. The company has also stated that it is advancing an in vivo Cystic Fibrosis (CF) program with support from the Cystic Fibrosis Foundation.

Beyond liver and lung indications, Prime Medicine reports efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, the company has disclosed a Phase 1/2 clinical program, PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD). Early data from two patients treated in this trial, as described in a New England Journal of Medicine publication cited by the company, showed rapid neutrophil and platelet engraftment, durable restoration of NADPH oxidase activity, early clinical benefit, and no clinically significant adverse events attributable to PM359, providing a first-in-human demonstration of Prime Editing’s safety and efficacy in that setting.

Research, development and collaborations

Prime Medicine’s disclosures indicate that the company’s strategy centers on advancing its in vivo liver-targeted programs in Wilson’s Disease and AATD, its CF program, and collaborations that can broaden the reach of its Prime Editing technology. The company has highlighted a partnership with Bristol Myers Squibb focused on Prime Edited CAR-T products, and support from the Cystic Fibrosis Foundation for its CF program. It has also described a universal liver lipid nanoparticle (LNP) delivery approach that it believes may enable efficiencies in preclinical development, manufacturing and clinical development for liver-targeted Prime Editors.

According to its public statements, Prime Medicine organizes its pipeline to prioritize diseases with well-understood biology and clear regulatory pathways, with the expectation that success in these initial indications can support expansion into additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases. The company has stated that these broader opportunities, if realized, could collectively impact millions of people.

Corporate and capital markets activity

Prime Medicine is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission as a public company. Its common stock trades on The Nasdaq Global Market under the symbol PRME. The company has used underwritten public offerings and at-the-market facilities to raise capital, as reflected in its Form 8-K filings describing an underwritten public offering of common stock and the termination of a prior at-the-market prospectus. It has also reported special stockholder meetings to consider matters such as the repricing of certain outstanding stock options under its equity plans.

In its SEC filings, Prime Medicine has described its use of cash, cash equivalents and investments to fund operating expenses, research and development activities, and capital expenditures, and has provided guidance on its expected cash runway based on current operating plans. The company has also furnished updated corporate presentations via Form 8-K to provide investors with additional information about its business, pipeline and strategy.

Location and sector classification

Prime Medicine’s principal executive offices are located in Cambridge, Massachusetts, and it operates within the Research and Development in Biotechnology industry, which falls under the broader Professional, Scientific, and Technical Services sector classification. Its activities, as described in its public communications, are focused on scientific research, preclinical development, clinical studies, and related corporate functions needed to advance gene editing-based therapeutic candidates.

Risk and regulatory context

As with other biotechnology companies developing investigational therapies, Prime Medicine’s SEC filings contain detailed risk factor disclosures. These include uncertainties related to product candidates entering clinical trials, authorization and conduct of preclinical and IND-enabling studies, obtaining regulatory approvals, development and optimization of new technologies, protection of intellectual property covering Prime Editing, the ability to enter into and maintain collaborations and license agreements, and general economic, industry and market conditions. The company also notes that forward-looking statements about its programs, timelines, partnerships and financial position are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

Summary

According to its public disclosures, Prime Medicine, Inc. is a biotechnology company listed on Nasdaq under the symbol PRME, focused on developing one-time curative genetic therapies based on its Prime Editing gene editing platform. With core areas of focus in liver, lung, and immunology and oncology, and named programs in Wilson’s Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, chronic granulomatous disease and Prime Edited CAR-T products, the company positions Prime Editing as a versatile technology that may be applicable across many potential indications. Its operations combine scientific research, clinical development, and capital markets activity within the biotechnology segment of the professional, scientific and technical services sector.

Stock Performance

$3.90
+1.56%
+0.06
Pre-marketLast updated: at
+0.5%
Performance 1 year
$869.7M

Prime Medicine (PRME) closed at $3.84 on November 17, 2026. Over the past 12 months, the price has gained 0.5%.

See what a $1,000 investment in PRME would be worth today

Average down calculator for PRME

PRME Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Prime Medicine has 10 recent news articles, with the latest published on . Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include offering, earnings, clinical trial, conferences. View all PRME news →

Financial Highlights

Prime Medicine generated $4.6M in revenue in FY2025, operating income reached -$208.3M, and net income was -$201.1M. Diluted earnings per share stood at -$1.35. The company generated -$162.6M in operating cash flow. The current ratio was 4.84, measuring current assets divided by current liabilities.

$4.6M
Revenue (FY2025)
-$201.1M
Net Income (FY2025)
-$162.6M
Operating Cash Flow

Upcoming Events

DEC
10
December 10, 2026 Financial

Underwriter option expiry

30‑day underwriter option to purchase up to $18.75M of additional Prime Medicine common stock expires 30 days after launch.
YEAR
2027
2027 Clinical

PM647 initial data

Initial clinical data for PM647 (Alpha-1 Antitrypsin Deficiency) expected in 2027 after FDA cleared study; readouts will be material.
H1
2027
H1 2027 Regulatory

PM359 BLA filing

Prime plans to submit a PM359 biologics license application in H1 2027; filing timing and acceptance will be material to regulators.
YEAR
2027
2027 Clinical

PM577a initial data

Initial clinical data for PM577a from global Phase 1/2 Wilson disease trial expected in 2027; trial startup is already underway.
H1
2027
H1 2027 Regulatory

PM359 potential BLA

Potential BLA submission for PM359 (chronic granulomatous disease) targeted in 1H 2027; PM359 has received FDA RMAT designation.
YEAR
2027
2027 Clinical

Initial clinical data

Expected first clinical data readout for PM577 in 2027
YEAR
2027
2027 Clinical

Clinical data readout

H1
2027
H1 2027 Regulatory

Wilson's Disease IND filing

Expected IND/CTA submission for Wilson’s Disease program
YEAR
2027
2027 Clinical

Initial clinical data expected

Initial clinical data from programs expected during 2027
YEAR
2027
2027 Clinical

Initial clinical data readout

Initial clinical data for PM577a anticipated in 2027 from the global Phase 1/2 trial; timing and sites to be announced.
YEAR
2027
2027 Clinical

WD clinical data readout

Initial clinical data readout for WD program expected
YEAR
2027
2027 Clinical

PM647 clinical readouts

First clinical readouts for PM647 in AATD expected
YEAR
2027
2027 Clinical

Initial clinical data release

Expected initial clinical data for Wilson’s Disease and AATD programs in 2027

Prime Medicine has 13 upcoming scheduled events. The next event, "Underwriter option expiry", is scheduled for December 10, 2026 (in 22 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the PRME stock price.

Short Interest History

Last 12 Months

Short interest in Prime Medicine (PRME) currently stands at 29.1 million shares, down 11.3% from the previous reporting period, representing 30.2% of the float. Since November 2025, short interest has increased by 48.2%.

Days to Cover History

Last 12 Months

Days to cover for Prime Medicine (PRME) currently stands at 4.8 days, down 13% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 4.8 to 18.6 days.

PRME Company Profile & Sector Positioning

Prime Medicine (PRME) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PRME often look at related companies in the same sector, including Jade Biosciences, Inc. (JBIO), Immatics N.V. (IMTX), Aktis Oncology, Inc. (AKTS), Verastem, Inc. (VSTM), and Corvus Pharmaceuticals, Inc. (CRVS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PRME's relative position within its industry.

Frequently Asked Questions

The current stock price of Prime Medicine (PRME) is $3.90 in pre-market trading as of November 18, 2026.

The market cap of Prime Medicine (PRME) is approximately $869.7M. Learn more about what market capitalization means .

The FY2025 revenue of Prime Medicine (PRME) is $4.6M, from its most recent completed fiscal year.

The FY2025 net income of Prime Medicine (PRME) is -$201.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Prime Medicine (PRME) is -$1.35 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Prime Medicine (PRME) is -$162.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Prime Medicine (PRME), current assets divided by current liabilities, was 4.84 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Prime Medicine (PRME) is -$208.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

Prime Medicine, Inc. is a biotechnology company that states it is dedicated to creating and delivering the next generation of gene editing therapies to patients. It is deploying its proprietary Prime Editing platform to develop a new class of differentiated one-time curative genetic therapies.

Prime Medicine describes Prime Editing as a versatile, precise and efficient gene editing technology designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. The company states that Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.

Prime Medicine reports that it is progressing a diversified portfolio of investigational therapeutic programs organized around three core areas of focus: liver, lung, and immunology and oncology. Within each area, it is initially focusing on high value programs targeting diseases with well-understood biology and clearly defined clinical development and regulatory paths.

In its public communications, Prime Medicine has identified PM577 as a Prime Editor candidate for H1069Q-driven Wilson’s Disease, PM647 as a development candidate for Alpha-1 Antitrypsin Deficiency, an in vivo Cystic Fibrosis program supported by the Cystic Fibrosis Foundation, and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.

Prime Medicine has reported Phase 1/2 clinical data with PM359 for p47phox chronic granulomatous disease, including two patients treated in the trial. According to the company, both patients experienced rapid neutrophil and platelet engraftment, durable restoration of NADPH oxidase activity, early clinical benefit, and no clinically significant adverse events attributable to PM359, providing a first-in-human demonstration of Prime Editing’s safety and efficacy in that setting.

Prime Medicine has disclosed efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. It has also stated that its in vivo Cystic Fibrosis program is supported by the Cystic Fibrosis Foundation.

Prime Medicine’s common stock trades on The Nasdaq Global Market under the ticker symbol PRME, as indicated in its press releases and SEC filings.

The company states that Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications. Over time, it intends to expand beyond its current pipeline to potentially include additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases.

Prime Medicine’s principal executive offices are located in Cambridge, Massachusetts, as stated in its definitive proxy materials filed with the U.S. Securities and Exchange Commission.

Prime Medicine’s SEC filings describe risks related to uncertainties in product candidates entering clinical trials, authorization and conduct of preclinical and IND-enabling studies, obtaining regulatory approvals, development and optimization of new technologies, protection of intellectual property for Prime Editing, the ability to enter into and maintain collaborations and license agreements, expectations about its cash runway, and general economic, industry and market conditions.